ARG1 — Arginase 1

ARG1 — Arginase 1

Overview

Pathway Diagram

ARG1 — Arginase 1

Overview

Pathway Diagram

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ARG1 — Arginase 1</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>ARG1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Arginase 1</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6q23.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>[383](https://www.ncbi.nlm.nih.gov/gene/383)</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>[608313](https://www.omim.org/entry/608313)</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>[P05089](https://www.uniprot.org/uniprot/P05089)</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000118526</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Hydrolase, manganese-dependent</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>High</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Spinal Cord</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Low</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">106 edges</a></td>
</tr>
</table>

ARG1 (Arginase 1) is a human gene located on chromosome 6q23.2 that encodes the cytosolic isoform of arginase, a metalloenzyme that catalyzes the final step of the urea cycle — the hydrolysis of L-arginine to L-ornithine and urea["^1"]. While its primary metabolic role is in the liver and kidney, ARG1 is also expressed in the brain, where it plays important roles in modulating nitric oxide (NO) production, polyamine synthesis, and immune cell function["^2"].

In the central nervous system, arginase activity competes with nitric oxide synthase (NOS) for the shared substrate L-arginine, making it a critical regulator of neuroinflammation and excitotoxicity. Dysregulation of ARG1 has been implicated in Alzheimer's disease, Parkinson's disease, and ALS["^3"].

Gene Overview

Protein Structure

Arginase 1 is a 322-amino acid protein that forms a homotrimeric quaternary structure. Each monomer contains a binuclear manganese cluster at the active site that is essential for catalytic activity[@dirosa2021].

Key Features:

• Molecular Weight: ~34.9 kDa
• Cellular Location: Cytosol
• Tissue Expression: Liver, kidney, brain (astrocytes, microglia, neurons)
• Induction: IL-4, IL-13, glucocorticoids
• Metal Cofactor: Manganese (Mn²⁺)
• Quaternary Structure: Homotrimer (three identical subunits)

Catalytic Mechanism

The arginase catalytic mechanism involves[@dirosa2021]:

Structural Domains

• N-terminal domain: Contains the active site with manganese cluster
• C-terminal domain: Contributes to trimer formation
• Active site pocket: Deep cleft for arginine binding
• Allosteric regions: Potential drug binding sites

Enzyme Kinetics

• Km for L-arginine: ~1-10 mM (varies by species)
• Vmax: High catalytic efficiency
• Inhibitors: Boronic acid derivatives, amino acids, metal chelators
• pH Optimum: 9.0-10.0 (optimal for urea production)

Function in the Brain

Nitric Oxide Regulation

ARG1 plays a crucial role in modulating nitric oxide signaling[@cheng2019]:

Polyamine Synthesis

The product of arginase activity, L-ornithine, is a precursor for polyamine synthesis[@lee2018]:

• Putrescine: Generated by ornithine decarboxylase
• Spermidine: Further converted by spermidine synthase
• Spermine: Final product by spermine synthase
• Polyamines are involved in: cell proliferation, protein synthesis, oxidative stress protection

Immune Modulation

In microglia and astrocytes[@gomez2019]:

• M2 Polarization: ARG1 is a marker of alternative (M2) activation
• Anti-inflammatory: M2 microglia are generally neuroprotective
• Wound Healing: Promotes tissue repair and remodeling
• Trophic Support: Secretes growth factors

M1/M2 Microglial Polarization

Microglial activation exists on a spectrum:

• M1 (Classical Activation): Pro-inflammatory, cytotoxic
• iNOS, TNF-α, IL-1β, IL-6
• Neurotoxic in chronic states
• M2 (Alternative Activation): Anti-inflammatory, reparative
• ARG1, CD206, YM1, Fizz1
• Neuroprotective functions

Role in Neurodegenerative Diseases

Alzheimer's Disease

ARG1 involvement in AD is complex[@parks2019]:

• Neuroinflammation: Altered arginase activity affects cytokine production and glial response to amyloid-beta
• NO Signaling: Modulates NOS activity and oxidative stress
• Memory: Arginase inhibition may improve memory in AD models
• Therapeutic Target: Arginase modulators being explored

Parkinson's Disease

In PD, ARG1 shows altered expression[@bingham2019]:

• Microglial Activation: Changes in ARG1 correlate with microglial activation state
• Neuroprotection: Arginase activity may protect dopaminergic neurons
• L-DOPA Response: Arginase may influence response to dopaminergic therapy
• α-Synuclein: Interaction with arginase affects aggregation

ALS

ARG1 dysregulation in ALS[@yang2018]:

• Motor Neuron Environment: Altered in SOD1 mouse models
• Glial Response: Microglial arginase expression changes during disease progression
• Therapeutic Potential: Modulating arginase may influence disease course
• Excitotoxicity: Arginase affects glutamate metabolism

Arginine Metabolism Pathway

The Urea Cycle

ARG1 catalyzes the final step of the urea cycle:

L-Arginine → L-Ornithine + Urea
↓
Putrescine → Spermidine → Spermine

Connection to Other Metabolic Pathways

• Gluconeogenesis: Ornithine can be converted to glucose
• Glutamate Synthesis: Ornithine → glutamate
• Proline Synthesis: Ornithine → proline
• Creatine Synthesis: Arginine → creatine

Therapeutic Strategies

Arginase Inhibitors

Several drug development approaches are underway[@dirosa2021]:

Clinical Trials

Current status:

• Cardiovascular: Arginase inhibitors in trials
• Neurological: Preclinical AD/PD models
• Combination: With existing therapies

Biomarker Potential

ARG1 and related metabolites may serve as[@robinson2018]:

• Markers of microglial activation
• Indicators of neuroinflammatory state
• Potential biomarkers for disease progression
• Therapeutic response markers

Animal Models

Knockout Studies

ARG1 knockout in mice reveals:

• Hyperammonemia: Impaired urea cycle function
• Growth Retardation: Developmental abnormalities
• Neurological Deficits: Behavioral changes
• Immune Dysregulation: Altered inflammatory responses

Transgenic Models

Transgenic overexpression shows:

• Improved Wound Healing: Enhanced tissue repair
• Reduced Inflammation: M2 polarization
• Neuroprotection: In some disease models
• Altered Metabolism: Changed polyamine levels

Expression Patterns

Cell-Type Specific Expression

• Astrocytes: High ARG1 expression, particularly in gray matter
• Microglia: Inducible expression, marks M2 polarization
• Neurons: Lower basal expression, activity-dependent
• Oligodendrocytes: Minimal expression

Species Differences

• Mice: Higher basal arginase expression
• Rats: Similar to human expression patterns
• Humans: More restricted expression, highly inducible

Regulatory Mechanisms

Transcriptional Regulation

ARG1 expression is controlled by[@moro2019]:

Signaling Pathways

Key signaling pathways regulating ARG1:

• JAK/STAT: IL-4/IL-13 signaling
• PI3K/Akt: Growth factor signaling
• MAPK: Stress-activated pathways
• NF-κB: Can be both positive and negative

Post-Transcriptional Regulation

• mRNA Stability: AU-rich elements in 3' UTR
• MicroRNAs: miR-155 targets ARG1, miR-182
• Alternative Splicing: Minor isoforms
• RNA-Binding Proteins: HuR, TTP involvement

Post-Translational Modifications

• Phosphorylation: Serine/threonine residues
• Acetylation: Lysine acetylation affects activity
• Ubiquitination: Targets for degradation
• Sumoylation: Affects protein localization

Genetic Associations

Polymorphisms

ARG1 polymorphisms have been studied in[@robinson2018]:

• Cardiovascular Disease: Association with hypertension
• Asthma: Reduced arginase activity
• Neurological Disorders: Conflicting results in AD/PD

Gene-Environment Interactions

• Smoking: Affects arginase expression
• Diet: Arginine availability influences metabolism
• Exercise: Upregulates arginase in muscle

Epigenetic Regulation

• DNA Methylation: Altered in disease states
• Histone Modifications: Acetylation increases expression
• Chromatin Accessibility: Tissue-specific regulation

Interactions with Other Proteins

Protein-Protein Interactions

• NOS isoforms: eNOS, iNOS, nNOS compete for substrate
• ODC: Polyamine synthesis pathway
• GATA factors: Transcriptional regulation
• 14-3-3 proteins: Phosphorylation-dependent binding

Metabolic Interactions

• Arginine: Direct substrate
• Ornithine: Direct product
• Urea: Direct product
• Polyamines: Downstream metabolites

Clinical Significance

Diagnostic Applications

• Biomarker: M2 microglial marker
• Disease Progression: Levels correlate with progression
• Therapeutic Monitoring: Response to therapy

Therapeutic Targeting

Targeting ARG1 in neurodegeneration involves:

Challenges

• Blood-Brain Barrier: Drug delivery
• Selectivity: Isoform specificity
• Timing: Intervention window
• Side Effects: Systemic arginase inhibition

Comparative Biology

Evolution

ARG1 is evolutionarily conserved:

• Vertebrates: Highly conserved sequence
• Invertebrates: Functional orthologs
• Bacteria: Different enzyme families
• Plants: Different enzyme families

Isoforms

• ARG1: Cytosolic, liver-type
• ARG2: Mitochondrial, kidney-type
• ARG3: Tissue-specific variants

Species Distribution

• Mice: Two arginase genes (Arg1, Arg2)
• Zebrafish: Conserved function
• Humans: ARG1, ARG2, ARG3

Future Research

Knowledge Gaps

• Precise role in specific neurodegenerative diseases
• Cell-type specific functions
• Long-term effects of modulation
• Interaction with other metabolic pathways
• Biomarker validation in clinical settings

Current Questions

Active areas of investigation include:

• How does ARG1 contribute to specific disease phenotypes?
• Can arginase modulation improve outcomes?
• What are the long-term effects of arginase targeting?
• What is the cell-type specific role in neurodegeneration?

Research Directions

• Single-cell studies: Cell-type specific roles
• Temporal dynamics: Time course of changes
• Mechanistic studies: Causal relationships
• Therapeutic development: Drug discovery

Emerging Technologies

Clinical Translation

Key considerations for bringing arginase-based therapies to clinic:

• Pharmacokinetics: Ensuring adequate brain penetration
• Target engagement: Measuring target inhibition in vivo
• Biomarker development: Patient selection and response monitoring
• Safety profiling: Long-term effects of modulation
• Combination strategies: Synergy with existing therapies

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Nitric Oxide Signaling](/mechanisms/nitric-oxide-signaling)
• [Microglia](/cell-types/microglia)
• [Astrocyte](/cell-types/astrocyte)
• [Polyamine Pathway](/mechanisms/polyamine-metabolism)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Urea Cycle](/mechanisms/urea-cycle)

External Links

• [NCBI Gene - ARG1](https://www.ncbi.nlm.nih.gov/gene/383)
• [UniProt - ARG1](https://www.uniprot.org/uniprot/P05089)
• [OMIM - Arginase Deficiency](https://www.omim.org/entry/207500)

Pathway Diagram

The following diagram shows the key molecular relationships involving ARG1 — Arginase 1 discovered through SciDEX knowledge graph analysis: